This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cramer's 'Mad Money' Recap: I Told You So

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- Today's rally rebuffed all the market's objections in spectacular fashion, Jim Cramer told "Mad Money" viewers Wednesday, showing just how wrong the bears were during the market selloff seven days ago.

Cramer said that just a week ago the markets were worried about a slowing U.S. economy, but today saw a good durable goods number along with price increases in both containerboard and steel, two very economically sensitive commodities.

He said the transports confirmed the data by rallying hard on the news, so much so that Cramer even recommended all three major airlines -- United Continental (UAL), Delta Air Lines (DAL) and US Airways (LCC).

The markets were also worried about Italy, noted Cramer, but JPMorgan Chase (JPM), the large international bank, shrugged off those fears. Meanwhile, Joy Global (JOY) told investors that demand is not slowing in China, another fear last week.

The list of worries included a weak U.S. consumer, but that was rebuffed by just about all of retail heading higher Wednesday. Even the restaurants were strong, noted Cramer. Housing continues to be strong, as Toll Brothers (TOL) was able to make up lost ground from last week as well.

Finally, there were worries over the Federal Reserve and the massive government budget cuts known as sequestration. Cramer said Ben Bernanke put the Fed fears to rest, while the defense stocks are soaring in the face of looming budget cuts.

Add it all together and Cramer said the bears couldn't have been more wrong when they were in the midst of their panic selling last week.

Executive Decision

In the "Executive Decision" segment, Cramer sat down with Dr. Harvey Berger, chairman and CEO of Ariad Pharmaceuticals (ARIA), a stock that's risen 33% since Cramer last spoke to Berger in June 2012. Ariad recently received Food and Drug Administration approval for Iclusig, an orphan drug to treat leukemia that is expected to cost $115,000 per year.

Berger said that it has only taken five years for Ariad to go from its first clinical trials to FDA approval, which is a very short time period in the biotech world. He said that speaks to the difference Iclusig is making in the lives of its patients. The drug is expected to generate over $1 billion a year for Ariad in the next few years.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,083.80 -2.83 -0.02%
S&P 500 1,987.98 +0.97 0.05%
NASDAQ 4,472.1080 -1.5890 -0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs